Automate theme → scenario → plan
In the app, we make it easy to go from investment themes to Scenario Lab to a full thesis plan — without the busywork.
Eli Lilly's Growth Momentum Amid Upgrades
LLY|September 16, 2026
Merkapital proprietary research generated from the same Thesis Plan engine (news narrative → scenario overlay → risk framework → listed-options context). For information only — not a recommendation or personalized advice.
Executive Summary
- •Thesis: Recent analyst upgrades and strong performance in obesity drug sales highlight Eli Lilly's growth potential, though competitive pressures and market dynamics pose risks.
- •Reference spot: $1,191.74 · Scenario-implied fair value: — · Upside anchor: $1,315.04 (~+10.3% vs spot)
- •Risk framework: Volatility-adjusted stop at $1,131.74 (~5.0% below spot); risk/reward 2.05 : 1 vs modeled upside anchor.
- •Derivatives: Listed options snapshot unavailable (API: Thank you for using Alpha Vantage! This is a premium endpoint. You may subscribe).
Overview metrics
Quantitative snapshot from the Merkapital dashboard (same fields as Stocks → Overview Metrics), frozen at Thesis Plan save time.
Merkapital proprietary research (public sample)
Key developments & media context
Catalyst / news flow (seed narrative)
The following item was flagged in Market Intelligence and used as the primary media input for this note. It frames the narrative that the Thesis Plan engine then maps into scenarios, risk/reward, and options structure — it is not a stand-alone fundamental view.
Headline-level classification and feed sentiment skew constructive (risk-on). We treat this item as the narrative seed for the bull / base / bear structure and scenario overlay that follow — not as a standalone forecast.
Primary headline
Lilly says Foundayo has captured over 30% of new US patients on oral weight-loss drugs
Feed tone label: Bullish.
LLY · LLY · LLY · LLY · LLY
Reuters.
https://www.reuters.com/legal/litigation/lilly-says-foundayo-has-captured-over-30-new-us-patients-oral-weight-loss-drugs-2026-09-14/
Merkapital proprietary research (public sample)
Revenue scenario
The following reflects consolidated revenue and segment mix assumptions recorded at the time this report was generated, benchmarked to the mapped segment disclosure and SEC-sourced consolidated revenue where applicable. Competitive positioning and filing references are provided for context only. These amounts represent hypothetical scenario inputs prepared in the research workflow and are not forecasts, targets, or projections of actual results.
Scenario basis: Segment mix and map baseline aligned to FY 2025 (period end 2025-12-31).
| Segment | Map % | Thesis % |
|---|---|---|
| Diabetes Care | 45.0% | 45.0% |
| Oncology | 25.0% | 25.0% |
| Neuroscience | 15.0% | 15.0% |
| Other Pharmaceuticals | 10.0% | 10.0% |
| Animal Health | 5.0% | 5.0% |
leader
$65.18B
FY 2025 (period end 2025-12-31)
Diabetes Care · Oncology · Neuroscience · Other Pharmaceuticals · Animal Health
Merkapital proprietary research (public sample)
Scenario Lab
Earnings and multiple assumptions from the Thesis Plan wizard (step 3), prior to the execution plan below.
- Last close
- $1,191.74
- Consensus EPS (next FY, baseline)
- —
- Scenario EPS
- —
- Forward P/E (baseline)
- —
- Scenario forward P/E
- —
- Street-implied (baseline)
- $1,315.04
- Scenario implied fair value
- $1,315.04
- Analyst target
- $1,315.04
- Scenario vs spot
- +10.3%
Frozen at Thesis Plan save; does not update with live quotes.
Merkapital proprietary research (public sample)
Valuation & Scenario Overlay
| Metric | Value |
|---|---|
| Last / model spot | $1,191.74 |
| Consensus analyst target (where available) | $1,315.04 |
| Scenario Lab implied price | — |
| Thesis upside anchor (options / R:R) | $1,315.04 |
| ATR-style volatility proxy (14d scale) | $40.00 |
| Annualized vol (model) | 33.3% |
| Risk per share (spot − stop) | $60.00 |
| Reward per share (anchor − spot) | $123.30 |
Merkapital proprietary research (public sample)
Risk Management & Invalidation
Volatility-adjusted stop: consider closing or reducing if price ≤ $1131.74 (entry − 1.5× ATR proxy using model volatility). Scenario upside anchor: $1315.04. Educational workflow only — not advice.
Merkapital proprietary research (public sample)
Listed Options — Expression of View
Structures are algorithmically selected from available chains (bull call spread; ~6m and ~12m anchors). Quotes may be delayed; liquidity and execution assumptions not modeled here.
API: Thank you for using Alpha Vantage! This is a premium endpoint. You may subscribe
Merkapital proprietary research (public sample)
Investment Thesis Map
Eli Lilly's Growth Momentum Amid Upgrades
Constructive angles
Eli Lilly's obesity drug Foundayo is capturing significant market share.
LLY
Foundayo has captured over 30% of new US patients on oral weight-loss drugs, indicating strong demand and market penetration.
Mechanism: Continued growth in the obesity drug segment can drive revenue and support stock price appreciation.
Analyst upgrades signal confidence in Eli Lilly's future performance.
LLY
Multiple analysts have upgraded LLY to 'Buy', reflecting positive sentiment and potential for stock price increases.
Mechanism: Upgrades can attract institutional investors and enhance market perception, leading to higher valuations.
Strong growth trajectory in obesity and diabetes treatments positions LLY favorably.
LLY
The company's focus on innovative treatments aligns with growing healthcare trends and patient needs.
Mechanism: Successful product launches and market adoption can lead to sustained revenue growth.
Cautious / bearish angles
Competitive pressures from other pharmaceutical companies could impact LLY's market share.
NVO, PFE
Competitors like Novo Nordisk (NVO) and Pfizer (PFE) are also focusing on obesity treatments, which could dilute LLY's market position.
Mechanism: Increased competition may lead to pricing pressures and reduced margins.
Market volatility and potential regulatory changes could negatively affect LLY's stock performance.
SPY
Broader market conditions and potential changes in healthcare regulations may create uncertainty for investors.
Mechanism: Negative sentiment in the market could lead to stock price declines regardless of company performance.
Second-order effects
- Increased investor confidence may lead to higher valuations for other biotech firms focused on obesity and diabetes.
- Market share shifts among obesity drug manufacturers could lead to strategic partnerships or acquisitions.
Risks & invalidation
- Failure to maintain market share in the obesity drug segment could lead to revenue shortfalls.
- Negative clinical trial results or regulatory setbacks could impact investor sentiment and stock performance.
Suggested news monitors
Eli Lilly obesity drug news · LLY analyst upgrades · Pharmaceutical competition in obesity treatments
This document is generated by Merkapital's research tooling for informational and educational purposes only. It does not constitute investment advice, a solicitation, or a recommendation to buy or sell any security or derivative. Scenario outputs depend on user inputs and model assumptions; actual results may differ materially.
Options involve substantial risk and are not suitable for all investors. Past performance does not guarantee future results.
Automate theme → scenario → plan
Build investment themes, stress-test them in Scenario Lab, and turn the winner into a thesis plan — faster than spreadsheets and copy-paste.
Create your 10x idea today